文献速递临床试验与 GCP医学人工智能与信息学

失眠与睡眠呼吸暂停共病的阶梯式照护管理:AIR研究方案

Stepped care management of insomnia co-occurring with sleep apnea: the AIR study protocol.
PubMed 文献 · Trials · 2022-09-24

本研究为双中心随机临床试验,采用序贯多分配随机试验(SMART)设计,检验阶梯式照护模型相对于标准气道正压(PAP)治疗的效果。研究纳入阻塞性睡眠呼吸暂停(OSA)与失眠共病患者,第一阶段随机接受PAP+在线认知行为失眠治疗(OCBT-I)或PAP+睡眠卫生教育,8周后评估失眠缓解(失眠严重指数<10);未缓解者再随机接受继续OCBT-I或转换为治疗师实施的CBT-I。主要结局为失眠缓解,次要结局包括主观和客观睡眠数据、疲劳、PAP依从性、嗜睡及日间警觉性等。

要点

  • OSA与失眠共病常见,既往研究对最佳管理方案指导有限。
  • 该SMART试验检验OCBT-I作为阶梯式照护第一阶段是否改善短期结局。
  • 对OCBT-I+PAP短期反应不佳者,再随机比较继续OCBT-I与转换为TCBT-I。

核心结论

  • 本研究将为OSA与失眠共病患者的最佳干预提供新信息,以指导未来临床决策过程。

研究设计与样本

  • 双中心随机临床试验,采用序贯多分配随机试验(SMART)设计,检验阶梯式照护模型相对于标准PAP治疗的效果。
  • 纳入OSA与失眠共病患者,完成基线评估后随机分配至第一阶段治疗:常规照护PAP+OCBT-I或常规照护PAP+睡眠卫生教育。
  • 8周后复评失眠;OCBT-I组达到缓解标准(失眠严重指数<10)者继续PAP但不接受额外失眠干预,并在额外8周后及3、6个月随访时完成结局测量。
  • OCBT-I组8周后未缓解者再随机分配至第二阶段治疗:继续扩展OCBT-I或转换为TCBT-I;第二阶段干预组及常规照护组在另一8周后及3、6个月随访时复评。
  • 主要结局为失眠缓解;次要结局包括主观和客观睡眠数据(睡眠时间、睡眠效率)、疲劳评分、PAP依从性、嗜睡评分、睡眠/觉醒功能评分及客观日间警觉性。

关键数值与推荐

  • 失眠缓解标准定义为失眠严重指数评分<10。
  • 第一阶段随机分组包括常规照护PAP+OCBT-I或常规照护PAP+睡眠卫生教育。
  • 第二阶段再随机分组包括继续扩展OCBT-I或转换为TCBT-I。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Obstructive sleep apnea (OSA) and insomnia are commonly co-occurring conditions that amplify morbidity and complicates the management of affected patients. Unfortunately, previous research provides limited guidance as to what constitutes the best and most practical management approach for this comorbid patient group. Some preliminary studies show that when cognitive behavioral insomnia therapy (CBT-I) is combined with standard OSA therapies for these patients, outcomes are improved. However, the dearth of trained providers capable of delivering CBT-I has long served as a pragmatic barrier to the widespread use of this therapy in clinical practice. The emergence of sophisticated online CBT-I (OCBT-I) programs could improve access, showing promising reductions in insomnia severity. Given its putative scalability and apparent efficacy, some have argued OCBT-I should represent a 1st-stage intervention in a broader stepped care model that allocates more intensive and less assessable therapist-delivered CBT-I (TCBT-I) only to those who show an inadequate response to lower intensity OCBT-I. However, the efficacy of OCBT-I as a 1st-stage therapy within a broader stepped care management strategy for insomnia comorbid with OSA has yet to be tested with comorbid OSA/insomnia patients. METHODS/DESIGN: This dual-site randomized clinical trial will use a Sequential Multiple Assignment Randomized Trial (SMART) design to test a stepped care model relative to standard positive airway pressure (PAP) therapy and determine if (1) augmentation of PAP therapy with OCBT-I improves short-term outcomes of comorbid OSA/insomnia and (2) providing a higher intensity 2nd-stage CBT-I to patients who show sub-optimal short-term outcomes with OCBT-I+PAP improves short and longer-term outcomes. After completing baseline assessment, the comorbid OSA/insomnia patients enrolled will be randomized to a 1st-stage therapy that includes usual care PAP + OCBT-I or UC (usual care PAP + sleep hygiene education). Insomnia will be reassessed after 8 weeks. OCBT-I recipients who meet "remission" criteria (defined as an Insomnia Severity Index score < 10) will continue PAP but will not be offered any additional insomnia intervention and will complete study outcome measures again after an additional 8 weeks and at 3 and 6 month follow-ups. OCBT-I recipients classified as "unremitted" after 8 weeks of treatment will be re-randomized to a 2nd-stage treatment consisting of continued, extended access to OCBT-I or a switch to TCBT-I. Those receiving the 2nd-stage intervention as well as the UC group will be reassessed after another 8 weeks and at 3- and 6-month follow-up time points. The primary outcome will be insomnia remission. Secondary outcomes will include subjective and objective sleep data, including sleep time, sleep efficiency, fatigue ratings, PAP adherence, sleepiness ratings, sleep/wake functioning ratings, and objective daytime alertness. DISCUSSION: This study will provide new information about optimal interventions for patients with comorbid OSA and insomnia to inform future clinical decision-making processes. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03109210 , registered on April 12, 2017, prospectively registered.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Eldridge-Smith ED, Manber R, Tsai S, et al. Stepped care management of insomnia co-occurring with sleep apnea: the AIR study protocol. Trials. 2022. PMID: 36153634. doi:10.1186/s13063-022-06753-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。